Accessibility StatementSkip Navigation NEW YORK, Nov. 7, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of$65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to $20.65 per share in cash. The Metsera Board of Directors has determined that the revised terms represent the best transaction ...